What are the recommended dosing regimens, contraindications, baseline screening, and monitoring requirements for sarilumab in adults with moderate-to-severe rheumatoid arthritis and in hospitalized COVID‑19 patients requiring supplemental oxygen?

Sarilumab Dosing, Monitoring, and Contraindications

Rheumatoid Arthritis: Recommended Dosing Regimen

For adults with moderate-to-severe rheumatoid arthritis, initiate sarilumab at 200 mg subcutaneously every 2 weeks, with dose reduction to 150 mg every 2 weeks if laboratory abnormalities (particularly neutropenia) develop. 1, 2

• The 200 mg every 2 weeks regimen produces numerically greater reductions in disease activity (50% vs 47% DAS28-CRP reduction) and more consistent neutrophil suppression (39% vs 31% ANC reduction) compared to 150 mg every 2 weeks 1
• Both doses demonstrate similar efficacy when combined with conventional synthetic DMARDs, with ACR20 response rates of 55.8% (150 mg) and 60.9% (200 mg) at 24 weeks in TNF-inhibitor inadequate responders 3
• Sarilumab can be administered as monotherapy or in combination with methotrexate or other conventional synthetic DMARDs 2, 3
• The autoinjector pen and prefilled syringe are bioequivalent, with 88% of patients rating the pen as "easy to use" 4

COVID-19: Dosing in Hospitalized Patients

For hospitalized COVID-19 patients requiring supplemental oxygen, sarilumab 200 mg or 400 mg intravenous as a single dose reduces mortality when combined with corticosteroids. 5

• Pooled analysis of IL-6 receptor antagonists (including sarilumab) showed mortality reduction with OR 0.87 (95% CI 0.79-0.96, p=0.007) 5
• Sarilumab-specific analysis demonstrated OR 0.88 (95% CI 0.73-1.07, p=0.19), with no meaningful difference from tocilizumab 5
• The mortality benefit is observed primarily in patients receiving concomitant glucocorticoids 5
• Greatest benefit occurs in patients requiring oxygen or non-invasive ventilation, with lesser effect in those already invasively ventilated 5

Baseline Screening Requirements

Before initiating sarilumab for rheumatoid arthritis, obtain:

• Complete blood count with differential (absolute neutrophil count, platelet count) 3, 6
• Hepatic transaminases (ALT/AST) 3, 6
• Lipid panel 2
• Tuberculosis screening per standard biologic DMARD protocols 2

No specific covariates require dose adjustment: body weight, rheumatoid factor status, anti-CCP status, and concomitant methotrexate use do not clinically meaningfully influence sarilumab pharmacokinetics or pharmacodynamics 1

Monitoring Requirements During Treatment

Monitor the following parameters regularly:

• Absolute neutrophil count: Check before each dose initially, then every 4-8 weeks once stable 3, 6

  • Neutropenia is the most common laboratory abnormality, occurring in both dose groups 4, 3
  • Reductions in ANC were not associated with increased infection rates in clinical trials 3
  • If ANC decreases significantly, reduce dose from 200 mg to 150 mg every 2 weeks 1, 2

• Hepatic transaminases (ALT/AST): Monitor every 4-8 weeks 3, 6

  • Transaminase elevations occur more frequently than with placebo 3
  • Dose reduction may be required for persistent elevations 2

• Platelet count: Monitor periodically as thrombocytopenia can occur with IL-6 inhibition 6

• Lipid profile: Assess 4-6 weeks after initiation and periodically thereafter, as IL-6 inhibition can increase LDL and total cholesterol 2

Contraindications and When to Withhold Treatment

Absolute contraindications:

• Active serious infection 5
• Hypersensitivity to sarilumab (though anaphylaxis was not reported in clinical trials) 6

Temporarily withhold sarilumab in the following situations:

• Following known SARS-CoV-2 exposure: Stop temporarily pending 2 weeks of symptom-free observation 5

  • Exception: In select circumstances with shared decision-making, IL-6 receptor inhibitors may be continued 5

• During active COVID-19 infection: Stop regardless of severity 5

  • Exception: May continue in select circumstances as part of shared decision-making 5

• Active serious bacterial infection: Discontinue immediately until infection clears completely 5

• Severe neutropenia: Hold or reduce dose based on ANC levels 1, 2

Restarting After Infection

For uncomplicated COVID-19 infections treated in ambulatory settings:

• Consider restarting sarilumab within 7-14 days of symptom resolution 5
• For asymptomatic patients with positive PCR, consider restarting 10-17 days after positive result 5

For more severe COVID-19 illness:

• Decisions regarding timing of reinitiation should be made case-by-case 5

Immunogenicity Considerations

Antidrug antibodies (ADAs) develop infrequently and do not impact efficacy or safety:

• Persistent ADAs occurred in 12.3% of patients receiving 150 mg and 6.1% receiving 200 mg every 2 weeks 6
• Neutralizing antibodies were present in 10.8% (150 mg) and 3.0% (200 mg) of patients 6
• All ADA titers were low, and ADA-positive patients showed no loss of efficacy or increased hypersensitivity reactions 6
• No cases of anaphylaxis were reported in clinical trials 6

Common Pitfalls to Avoid

• Do not continue sarilumab during active serious infection (unlike hydroxychloroquine in SLE, which may be continued) 5
• Do not use sarilumab for COVID-19 without concomitant corticosteroids, as mortality benefit is primarily observed in patients receiving glucocorticoids 5
• Do not assume neutropenia requires discontinuation—dose reduction to 150 mg every 2 weeks is often sufficient 1, 2
• Do not overlook lipid monitoring, as IL-6 inhibition increases cholesterol levels requiring management 2